FIMAN Biotechnology and Fudan University Jointly Establish University-Enterprise Joint Laboratory for Innovative Active Collagen Materials

May 14, 2026 —Fiman Biotechnology and Fudan University officially launched the Joint Laboratory for Innovative Active Collagen Materials (the “Joint Laboratory”) at the School of Life Sciences, Fudan University. In collaboration with the School of Biomedical Engineering & Technology Innovation and the Zhangjiang Research Institute of Fudan University, the Joint Laboratory will focus on basic research, cutting-edge technology development, and industrial translation of active bovine collagen.

The ceremony was attended by university leaders of Fudan University, the management team of Fiman Biotechnology, leaders from the School of Biomedical Engineering & Technology Innovation and the Zhangjiang Research Institute, as well as interdisciplinary top experts.


Strong University-Enterprise Alliance Leading Global Collagen Innovation

Against the backdrop of China’s 15th Five-Year Plan prioritizing biomaterials and healthcare, and driving industry-university-research integration, collagen stands as a core strategic material for tissue repair, high-end medical devices, and regenerative medicine. It meets surging consumer demand for anti-aging and youth preservation, unlocking a hundred-billion-yuan market opportunity.

While China boasts a robust regulatory system, leading safety standards, the world’s most complete collagen industrial chain, and top-tier patents, clinical research, and market scale, gaps remain in basic theory, core technology breakthroughs, and international standard-setting. Addressing these bottlenecks requires deep industry-university-research collaboration.

Fudan University has profound academic strengths in life sciences, polymer materials, phenomics, artificial intelligence, and clinical medicine. Fiman Biotechnology, a pioneer in active collagen for over two decades, was among the first Chinese enterprises to secure Class III medical device approval for bovine collagen. This alliance translates President Xi Jinping’s “Four Orientations” — toward global tech frontiers, economic mainstays, major national needs, and people’s health — from vision to action.


“We must bridge the ‘last mile’ between innovation and industrial chains,” said Professor Peng. “This partnership aligns with the ‘Four Orientations.’ Leveraging Fudan’s academic strengths and Feiman’s industrial expertise, we aim to conquer ‘bottleneck’ technologies in active bovine collagen, build three highlands for original innovation, industry-education integration, and healthcare services, and accelerate the translation of research from ‘shelves to shelves’ for public health.”


“Our visions and missions align closely,” said Secretary Guo. “We will mobilize interdisciplinary talent, share advanced research platforms, and deepen industry-education integration. Focused on key bovine collagen technologies, we strive to build a benchmark for integrated industry-university-research and application, driving high-quality growth in China’s collagen sector.”

National-Grade Collagen Empowering Industrial Upgrading
With 20+ years of expertise, Fiman Biotechnology upholds “national-grade collagen quality” and operates a full-chain quality control system — from EU-standard medical cattle farms and raw material optimization to process innovation, product development, and clinical validation. The company has co-authored expert consensus and group standards for periorbital and perioral anti-aging, advancing safe, effective collagen solutions.

Feiman has long championed industry-university-research collaboration, partnering with Sichuan University, Shaanxi University of Science & Technology, Jilin University, and clinical experts to streamline “basic research-clinical application-industrial translation” and shape industry standards. The Fudan alliance marks a pivotal step in building an integrated “research-production-application” ecosystem for active collagen.

“This partnership unites Fudan’s research prowess with Feiman’s industrial capabilities,” said Mr. Wu. “We aim to build a global hub for collagen innovation, translation, and standard-setting. By leveraging our full-chain strengths, we will rapidly turn lab breakthroughs into clinically viable, market-approved products — realizing the vision: ‘Global collagen looks to China; China leads the world.’”